1026076-88-9

Usage

Uses

Used in Pharmaceutical Industry:
7-chloro-5-methyl-2-phenyl-1H-pyrrolo[3,2-b]pyridine is used as a potential pharmaceutical candidate for various applications due to its unique structural features. The chlorine atom and phenyl group provide opportunities for interactions with biological targets, which may contribute to the compound's biological activities. The fused ring system and other substituents can also affect the compound's chemical and physical properties, making it a promising candidate for further research and exploration in the pharmaceutical field.
Further research and exploration of 7-chloro-5-methyl-2-phenyl-1H-pyrrolo[3,2-b]pyridine are required to determine its exact potential and uses in the pharmaceutical industry. This may include evaluating its efficacy in treating specific diseases, understanding its mechanism of action, and assessing its safety and toxicity profile. By harnessing the compound's structural features and potential biological activities, it may be possible to develop novel therapeutic agents with improved efficacy and selectivity.

Upstream product

• 237435-17-5 3-amino-4-chloro-6-methyl-2-(2-phenylethynyl)pyridine 
• 536-74-3 phenylacetylene 
• 237435-16-4 6-bromo-2,4-dichloropyridin-3-ylamine 
• 5975-12-2 2,4-dichloro-3-nitro-pyridine 
• 89282-12-2 2,4-dihydroxy-3-nitropyridine 
• 173772-63-9 2,4-dichloropyridin-3-ylamine 
• 626-03-9 3-deazauracil 

Relevant academic research and scientific papers

Compounds and methods which modulate feeding behavior and related diseases

There are provided compounds, compositions and methods of use thereof in the modulation of feeding behavior, obesity, diabetes, cancer (tumor), inflammatory disorders, depression, stress related disorders, Alzheimer's disease and other disease conditions.

Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists

Neuropeptide Y (NPY) has been shown to play an important role in the regulation of food intake and energy balance. Pharmacological data suggests that the Y5 receptor subtype contributes to the effects of NPY on appetite, and therefore a Y5 antagonist might be a useful therapeutic agent for the treatment of obesity. In attempts to identify potential Y5 antagonists, a series of pyrrolo[3,2-d]pyrimidine derivatives was prepared and evaluated for their ability to bind to Y5 receptors in vitro. We report here the synthesis and initial structure-activity relationship investigations for this class of compounds. The target compounds were prepared by a variety of synthetic routes designed to modify both the substitution and the heterocyclic core of the pyrrolo[3,2-d]pyrimidine lead 1. In addition to identifying several potent Y5 antagonists for evaluation as potential antiobesity agents, a pharmacophore model for the human Y5 receptor is presented.